Clinical Trials Logo

Mature B-Cell Malignancies clinical trials

View clinical trials related to Mature B-Cell Malignancies.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04277637 Recruiting - Clinical trials for Mature B-Cell Malignancies

Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies

Start date: March 24, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib and obinutuzumab.